HIV Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
Market Overview:
The global HIV drugs market size reached US$ 30.5 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 38.8 Billion by 2028, exhibiting a growth rate (CAGR) of 3.95% during 2023-2028.
Human Immunodeficiency Virus (HIV) is a chronic and life-threatening disease which can be transferred from one person to another through blood-to-blood and sexual contact. It is a virus which attacks immune cells known as CD-4 cells, making body susceptible to infections and other diseases. Over the years, the rising prevalence of HIV disease worldwide has positively influenced the demand for HIV drugs. HIV drugs help in preventing the multiplication of HIV, thereby reducing the risk of its transmission.
One of the primary factors catalysing the growth of the global HIV drugs market is increase in the prevalence of HIV and its diagnosis. Apart from this, the market is also influenced by a rise in the number of government initiatives for spreading the awareness amongst people regarding causes, symptoms and treatments. Moreover, the introduction of generic drugs, which are cost-effective and chemically identical to branded drugs, act as another factor that is contributing towards the demand for HIV drugs.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global HIV drugs market report, along with forecasts at the global and regional levels from 2023-2028. Our report has categorized the market based on drug class and distribution channel.
Breakup by Drug Class:
One of the primary factors catalysing the growth of the global HIV drugs market is increase in the prevalence of HIV and its diagnosis. Apart from this, the market is also influenced by a rise in the number of government initiatives for spreading the awareness amongst people regarding causes, symptoms and treatments. Moreover, the introduction of generic drugs, which are cost-effective and chemically identical to branded drugs, act as another factor that is contributing towards the demand for HIV drugs.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global HIV drugs market report, along with forecasts at the global and regional levels from 2023-2028. Our report has categorized the market based on drug class and distribution channel.
Breakup by Drug Class:
North America
Europe
Asia Pacific
Middle East and Africa
Latin America
Region-wise, the market has been segmented into Europe, Asia Pacific, North America, Middle East and Africa and Latin America. Amongst these, North America is the leading market accounting for the majority of the global market.
Competitive Landscape:
The competitive landscape of the market has also been examined with some of the key players being Boehringer Ingelheim International GmbH, Merck & Co., Inc., ViiV Healthcare, AbbVie, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Gilead Sciences, Inc., Johnson & Johnson, Cipla Limited, Daiichi Sankyo, Emcure, Hetero Drugs, and Mylan.
This report provides a deep insight into the global HIV drugs market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the HIV drugs market in any manner.
Key Questions Answered in This Report
1. What was the size of the global HIV drugs market in 2022?
2. What is the expected growth rate of the global HIV drugs market during 2023-2028?
3. What has been the impact of COVID-19 on the global HIV drugs market?
4. What are the key factors driving the global HIV drugs market?
5. What is the breakup of the global HIV drugs market based on the drug class?
6. What is the breakup of the global HIV drugs market based on the distribution channel?
7. What are the key regions in the global HIV drugs market?
8. Who are the key players/companies in the global HIV drugs market?
- 1 Preface
- 2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
- 3 Executive Summary
- 4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
- 5 Global HIV Drugs Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Price Analysis
- 5.5 Market Breakup by Drug Class
- 5.6 Market Breakup by Distribution Channel
- 5.7 Market Breakup by Region
- 5.8 Market Forecast
- 5.9 SWOT Analysis
- 5.9.1 Overview
- 5.9.2 Strengths
- 5.9.3 Weaknesses
- 5.9.4 Opportunities
- 5.9.5 Threats
- 5.10 Value Chain Analysis
- 5.10.1 Overview
- 5.10.2 Research and Development
- 5.10.3 Raw Material Procurement
- 5.10.4 Manufacturing
- 5.10.5 Marketing
- 5.10.6 Distribution
- 5.10.7 End-Use
- 5.11 Porters Five Forces Analysis
- 5.11.1 Overview
- 5.11.2 Bargaining Power of Buyers
- 5.11.3 Bargaining Power of Suppliers
- 5.11.4 Degree of Competition
- 5.11.5 Threat of New Entrants
- 5.11.6 Threat of Substitutes
- 6 Market Breakup by Drug Class
- 6.1 Nucleoside Reverse Transcriptase Inhibitors
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Multi-Class Combination Products
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Protease Inhibitors
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 HIV Integrase Strand Transfer Inhibitors
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
- 6.5 Non-Nucleoside Reverse Transcriptase Inhibitors
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
- 6.6 Entry Inhibitors — CCR5 Co-Receptor Antagonist
- 6.6.1 Market Trends
- 6.6.2 Market Forecast
- 6.7 Fusion Inhibitors and Others
- 6.7.1 Market Trends
- 6.7.2 Market Forecast
- 7 Market Breakup by Distribution Channel
- 7.1 Hospital Pharmacies
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Retail Pharmacies
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Online Pharmacies
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Others
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 8 Market Breakup by Region
- 8.1 North America
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Europe
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Asia Pacific
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Middle East and Africa
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
- 8.5 Latin America
- 8.5.1 Market Trends
- 8.5.2 Market Forecast
- 9 HIV Drugs Manufacturing Process
- 9.1 Product Overview
- 9.2 Raw Material Requirements
- 9.3 Manufacturing Process
- 9.4 Key Success and Risk Factors
- 10 Competitive Landscape
- 10.1 Market Structure
- 10.2 Market Breakup by Key Players
- 10.3 Profiles of Key Players
- 10.3.1 Boehringer Ingelheim International GmbH
- 10.3.2 Merck & Co., Inc.
- 10.3.3 ViiV Healthcare
- 10.3.4 AbbVie
- 10.3.5 F. Hoffmann-La Roche Ltd.
- 10.3.6 Teva Pharmaceutical Industries Ltd.
- 10.3.7 Bristol-Myers Squibb
- 10.3.8 Gilead Sciences, Inc.
- 10.3.9 Johnson & Johnson
- 10.3.10 Cipla Limited
- 10.3.11 Daiichi Sankyo
- 10.3.12 Emcure
- 10.3.13 Hetero Drugs
- 10.3.14 Mylan
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook